SOT 62nd Annual Meeting and ToxExpo, March 19-23 2023, Nashville, Tennessee, USA
Fiona Chapman1, Luuk de Haan2, Linda Gijzen2, Edgar Trelles Sticken3, Roman Wieczorek3, Sarah Jean Pour3, Liam Simms1, Matthew Stevenson1
1Imperial Brands PLC, 121 Winterstoke Road, Bristol, BS3 2LL, UK;
2Mimetas B.V., Biopartner Building 5, De Limes 7, 2342 DH Oegstgeest, the Netherlands;
3Reemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC company, Albert-Einstein-Ring-7, D-22761, Hamburg, Germany
INTRODUCTION
Cigarette smoking is a cause of serious diseases in smokers, including heart disease; atherosclerosis is reportedly responsible for the development of most heart diseases. Atherosclerosis progresses through a pathway of endothelial dysfunction, lipid infiltration, macrophage recruitment and vascular remodelling, and can be driven by exposure to exogenous agents such as some of the harmful and potentially harmful compounds present in cigarette smoke. However, the development of next generation nicotine delivery products, such as electronic nicotine delivery systems and heated tobacco products, offers adult smokers, uninterested or unwilling to quit smoking, potentially reduced harm alternatives to continued cigarette smoking. NGPs present an attractive harm reduction alternative because they produce significantly fewer and lower levels of HPHCs compared to cigarettes.
